Trial
NCT01457131
Modified White Blood Cells That Secrete IL-2 and Express a Protein That Targets the ESO-1tumor Protein for Metastatic Cancer
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
National Cancer Institute (NCI)
Collaborators
—
Condition
Metastatic Cancer
Intervention
Fludarabine
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-01-08